华氏巨球蛋白血症诊治进展  

Diagnosis and treatment progress of Waldenström macroglobulinemia

作　　者：邓晶晶 陈文明[1] Deng Jingjing;Chen Wenming(Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院血液科,100020

出　　处：《白血病．淋巴瘤》2020年第11期645-647,共3页Journal of Leukemia & Lymphoma

基　　金：国家科技重大专项(2018ZX09733003)。

摘　　要：第25届欧洲血液学会(EHA)年会于2020年6月11日至21日以网络会议的形式召开,会议重点讨论了利用循环游离DNA(cfDNA)检测华氏巨球蛋白血症(WM)患者MYD88突变和CXCR4突变的意义,并探讨了布鲁顿酪氨酸激酶抑制剂、含利妥昔单抗治疗方案在一线和复发WM患者中的临床研究结果。The 25th Congress of the European Hematological Society(EHA)was held in the form of a virtual edition from June 11 to 21,2020,which focused on the significance of the detection of MYD88 and CXCR4 mutations in Waldenström macroglobulinemia(WM)patients by using circulating free DNA(cfDNA),as well as the clinical results of Bruton tyrosine kinase inhibitors and treatment regimen including rituximab in the front-line and relapsed WM patients.

关 键 词：Waldenström巨球蛋白血症 基因诊断 治疗结果 

分 类 号：R733.1[医药卫生—肿瘤]